Obesity. Overweight and obesity
Conditions
Interventions
Intervention 1: Intervention group: acarbose is administrated for three month with 300 mg .At first it is prescribed with low dose 25 mg three times a day,and gradually placebo dose is increased ti
Sponsors
Endocine Research Center of Isfahan University of Medical Science
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: BMI=30 or more than 30 Affected by metabolic syndrome Female Age between 20_50 years
Exclusion criteria
Exclusion criteria: Chronic disease beside metabolic syndrome Non cooperative Consuming anti Lipid drugs Consuming Metformin in past year Weight loss or diet in past year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body weight. Timepoint: At the first visit and each two weeks after three month of consumption of total dose of drug or dose of patient tolerance. Method of measurement: Body weight scales.;Height. Timepoint: At first visit and last visit. Method of measurement: Height gauge.;Waist. Timepoint: At first visit and last visit. Method of measurement: Strip meter.;Fasting blood suger. Timepoint: At first visit and end of study. Method of measurement: Enzymatic lab study.;Insulin level of serum. Timepoint: At first visit and end of study. Method of measurement: ELISA method.;Epicardial fat thickness. Timepoint: At first visit and end of study. Method of measurement: Echocardiography.;Body Mass Index (BMI). Timepoint: At first visit and end of study. Method of measurement: BMI = kg/m2 person's weight in kilograms and m2 is their height in metres squared. | — |
Secondary
| Measure | Time frame |
|---|---|
| Flatulence. Timepoint: Each two weeks. Method of measurement: Questioner. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Noushin Khalili
Esfahan University of Medical Sciences
Outcome results
None listed